taurolidine

Trade name: Defencath

Small moleculeexperimental

Taurolidine is an antimicrobial that is used to prevent infections in catheters. Side effects and the induction of bacterial resistance is uncommon. It is also being studied as a treatment for cancer. — Wikipedia

Clinical trial activity

12 trials · 18 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
2
Phase 4
4

Earliest trial started Mar 1, 2001 (NCT00021034)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Cell wallDISRUPTING AGENT

    Cell wall disrupting agent

    Interacts with bacterial cell wall and also disrupts adhesion to surfaces.

  • Lipopolysaccharide (LPS) inhibitor

Chemistry & pharmacology

Loading structure…

SMILES

O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1
Mol. weight
284.36 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

First in class

Sources

Also known as

  • 4,4'-methylenebis-(tetrahydro-1,2,4-thiadiazine- 1,1-dioxide)
  • bis- (1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)methane
  • bis(1,1-dioxo-perhydro-1,2,4-thiadiazinyl-4)methane
  • hep500
  • tauroflex
  • tauroflex
  • tauroflex
  • tauroflex
  • tauroflex
  • taurolidine
  • taurolidine
  • taurolidine
  • taurolidine
  • taurolidine
  • taurolidine
  • taurolidine
  • taurolin
  • taurolin
  • tauroline
  • tauroline

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07310069Phase 2May 1, 2025Jiao Tong University
NCT07074821Phase 2Mar 1, 2023Government of Oman
NCT04093895Phase 2Aug 26, 2019Geistlich Pharma AG, PerioHealth Clinic Houston
NCT03539718Phase 4May 15, 2018Ain Shams University
NCT02651428Phase 3Dec 1, 2015CorMedix, Davita Clinical Research, Frenova Renal Research, JMI Laboratories, PPD, Spectra Clinical Research
NCT02313883Phase 1/Phase 2 (Phase 2)Jul 1, 2015Geistlich Pharma AG, PerioHealth Clinic Houston, University of Michigan
NCT02515201Phase 4Sep 1, 2014Federal University of Rio Grande do Sul
NCT02868697Phase 4Nov 1, 2013Hamad Medical Corporation
NCT02009189Phase 4Nov 1, 2012Stanley Dudrick's Memorial Hospital
NCT00321165Phase 3Jun 1, 2006Radboud University
NCT00022360Phase 1May 1, 2001Cornell University, National Cancer Institute (NCI)
NCT00021034Phase 1Mar 1, 2001Cornell University, National Cancer Institute (NCI)
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (18)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cornell UniversityAcademic/Hospital2212001
Geistlich Pharma AGFor profit2212015
National Cancer Institute (NCI)Government2012001
PerioHealth Clinic HoustonAcademic/Hospital2012015
Ain Shams UniversityAcademic/Hospital1112018
CorMedixFor profit1112015
Davita Clinical ResearchFor profit1012015
Federal University of Rio Grande do SulAcademic/Hospital1112014
Frenova Renal ResearchFor profit1012015
Government of OmanGovernment1112023
Hamad Medical CorporationFor profit1112013
Jiao Tong UniversityAcademic/Hospital1112025
JMI LaboratoriesFor profit1012015
PPDFor profit1012015
Radboud UniversityAcademic/Hospital1112006
Spectra Clinical ResearchFor profit1012015
Stanley Dudrick's Memorial HospitalAcademic/Hospital1112012
University of MichiganAcademic/Hospital1012015
18 organizations
Page 1 / 1